Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson’s disease

Written by Angelo Antonini, Weining Z Robieson, Lars Bergmann, Ashley Yegin & Werner Poewe

Does a patient’s age and disease duration in Parkinson’s affect the efficacy of their treatment with levodopa-carbidopa intestinal gel? Antonini et al. conducted a post hoc analysis of patient data from the GLORIA study to evaluate the impact of these factors on quality of life and activity of daily living outcomes. Read the abstract below to find out more on this new study, or read the full-text article in Neurodegenerative Disease Management here. Aim: To determine if age and Parkinson’s disease duration at therapy initiation influence the efficacy of levodopa-carbidopa intestinal gel (LCIG) on quality of life and activities of...

To view the full article, please register now for access

It's completely free